Emergent Biosolutions Net Income 2007-2021 | EBS

Emergent Biosolutions net income from 2007 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Emergent Biosolutions Annual Net Income
(Millions of US $)
2020 $305
2019 $55
2018 $63
2017 $83
2016 $52
2015 $63
2014 $37
2013 $31
2012 $24
2011 $23
2010 $52
2009 $31
2008 $21
2007 $23
2006 $23
2005 $16
Emergent Biosolutions Quarterly Net Income
(Millions of US $)
2021-09-30 $-33
2021-06-30 $5
2021-03-31 $70
2020-12-31 $185
2020-09-30 $40
2020-06-30 $93
2020-03-31 $-13
2019-12-31 $47
2019-09-30 $43
2019-06-30 $-10
2019-03-31 $-26
2018-12-31 $-3
2018-09-30 $21
2018-06-30 $50
2018-03-31 $-5
2017-12-31 $34
2017-09-30 $34
2017-06-30 $5
2017-03-31 $10
2016-12-31 $37
2016-09-30 $21
2016-06-30 $-11
2016-03-31 $4
2015-12-31 $33
2015-09-30 $37
2015-06-30 $14
2015-03-31 $-22
2014-12-31 $30
2014-09-30 $22
2014-06-30 $5
2014-03-31 $-20
2013-12-31 $15
2013-09-30 $13
2013-06-30 $10
2013-03-31 $-8
2012-12-31 $16
2012-09-30 $7
2012-06-30 $8
2012-03-31 $-7
2011-12-31 $29
2011-09-30 $2
2011-06-30 $14
2011-03-31 $-21
2010-12-31 $26
2010-09-30 $13
2010-06-30 $10
2010-03-31 $3
2009-12-31 $4
2009-09-30 $1
2009-06-30 $15
2009-03-31 $11
2008-12-31 $1
2008-09-30 $10
2008-06-30 $2
2008-03-31 $7
2007-12-31 $28
2007-09-30 $3
2007-06-30 $-5
2007-03-31 $-3
2006-12-31 $26
2006-09-30 $4
2006-06-30 $-3
2006-03-31 $-5
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.254B $1.555B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90